RayKnowChina Research Map
Shortlist

Open clinical trials in mainland China

4,406 open trials registered on ClinicalTrials.gov with at least one of 401 hospitals on this site as lead sponsor or study site, as registered on 8 Nov 2026. Newest posted first; filter by disease, date posted, the registered age and sex, phase and city.

Not a ranking or a recommendation. Whether someone can take part is decided by the study team. Trials registered only in China’s own registry (ChiCTR) are not included.

Trials

4,406 trials

  1. Recruiting

    Exploratory Clinical Study of Autologous Tumor-Infiltrating Lymphocytes (TIL) Injection

    Lung cancer

    Led by Tongji Hospital. . Start date 2025-04. NCT07947043

    Phase
    Phase 1
    Ages
    18–75
    Where
    Wuhan
    1
    18–75
    Wuhan1 listed hospital
  2. Not yet recruiting

    Comparing Single-session Versus Fractionated Stereotactic Radiotherapy for Elderly and Frail Patients With Early-stage Non-small Cell Lung Cancer.

    Lung cancer

    Led by Quanzhou First Hospital, Fujian Medical University. . Start date 2027-01. NCT07944313

    Phase
    Phase 2
    Ages
    60–90
    Where
    Quanzhou
    2
    60–90
    Quanzhou1 listed hospital
  3. Not yet recruiting

    Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure

    Lymphoma

    Led by Tianjin Medical University Cancer Institute & Hospital. . Start date 2026-12. NCT07944651

    Phase
    Phase 2
    Ages
    18 and over
    Where
    Tianjin
    2
    18 and over
    Tianjin1 listed hospital
  4. Not yet recruiting

    Function-Friendly Semi-Fowler Positioning for Coronary Angiography and PCI

    Coronary heart disease

    Led by Zhongshan Hospital, Fudan University. . Start date 2026-11. NCT07944716

    Phase
    Not stated
    Ages
    18–75
    Where
    Shanghai
    Not stated
    18–75
    Shanghai1 listed hospital
  5. Not yet recruiting

    Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma

    Lymphoma

    Led by Fudan University Shanghai Cancer Center. . Start date 2026-11. NCT07945353

    Phase
    Phase 2
    Ages
    18 and over
    Where
    Shanghai
    2
    18 and over
    Shanghai1 listed hospital
  6. Recruiting

    Multimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction

    Lymphoma

    Led by Chinese PLA General Hospital. . Start date 2026-01. NCT07941063

    Phase
    Not stated
    Ages
    18 and over
    Where
    Beijing
    Not stated
    18 and over
    Beijing1 listed hospital
  7. Recruiting

    Pragmatic AI-Assisted Lung Cancer Translational Study

    Lung cancer

    Led by Sir Run Run Shaw Hospital; 1 listed hospital as study site. . Start date 2026-08. NCT07941128

    Phase
    Not stated
    Ages
    18 and over
    Where
    Hangzhou, Zhengzhou
    Not stated
    18 and over
    Hangzhou, Zhengzhou2 listed hospitals
  8. Not stated
    18–70Women only
    Tianjin1 listed hospital
  9. Not yet recruiting

    Multimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and Planning

    Breast cancer

    Led by Sun Yat-sen Memorial Hospital. . Start date 2026-11. NCT07943494

    Phase
    Not stated
    Ages
    Not stated
    Where
    Guangzhou
    Not stated
    Not stated
    Guangzhou1 listed hospital
  10. Recruiting

    Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification

    Glioma

    Led by Beijing Tiantan Hospital. . Start date 2026-07. NCT07940231

    Phase
    Not stated
    Ages
    18 and over
    Where
    Beijing
    Not stated
    18 and over
    Beijing1 listed hospital
  11. Not yet recruiting

    Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Lymphoma

    Lead sponsor is not a listed hospital; 1 listed hospital as study site. . Start date 2026-12. NCT07938619

    Phase
    Phase 2
    Ages
    18 and over
    Where
    Guangzhou
    2
    18 and over
    Guangzhou1 listed hospital
  12. Recruiting

    Cardiopulmonary Exercise Active Health Cohort Study

    Coronary heart disease

    Led by Peking University Third Hospital. . Start date 2026-05. NCT07935187

    Phase
    Not stated
    Ages
    18–80
    Where
    Beijing
    Not stated
    18–80
    Beijing1 listed hospital
  13. Recruiting

    Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)

    Lymphoma

    Led by Tongji Hospital. . Start date 2025-10. NCT07934537

    Phase
    Phase 4
    Ages
    18–70
    Where
    Shanghai
    4
    18–70
    Shanghai1 listed hospital
  14. Not yet recruiting

    Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

    Lung cancer

    Led by Affiliated Cancer Hospital of Guizhou Medical University. . Start date 2026-10. NCT07936578

    Phase
    Phase 2
    Ages
    18–75
    Where
    Guiyang
    2
    18–75
    Guiyang1 listed hospital
  15. Recruiting

    Thalidomide for Preventing Radiation-Induced Dermatitis in Breast Cancer Patients

    Breast cancer

    Led by First Affiliated Hospital of Guangxi Medical University. . Start date 2026-11. NCT07933653

    Phase
    Not stated
    Ages
    18–70, women only
    Where
    Nanning
    Not stated
    18–70Women only
    Nanning1 listed hospital
  16. Recruiting

    Liver Metastasis in Pancreatic Ductal Adenocarcinoma: Regulatory Mechanisms and Clinical Significance

    Pancreatic cancer

    Led by Second Affiliated Hospital of Nanjing Medical University. . Start date 2026-10. NCT07933952

    Phase
    Not stated
    Ages
    18–80
    Where
    Nanjing
    Not stated
    18–80
    Nanjing1 listed hospital
  17. Not yet recruiting

    AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP

    Coronary heart disease

    Led by Union Hospital. . Start date 2026-11. NCT07933757

    Phase
    Not stated
    Ages
    18 and over
    Where
    Wuhan
    Not stated
    18 and over
    Wuhan1 listed hospital
  18. Recruiting

    A Phase I Clinical Study of YN003 in the Treatment of Glioma

    Glioma

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sites. . Start date 2026-10. NCT07929909

    Phase
    Phase 1
    Ages
    18–70
    Where
    Beijing
    1
    18–70
    Beijing2 listed hospitals
  19. Not yet recruiting

    Clinical Study on Fuzheng Jiedu Huayu Therapy in Combination With Chemotherapy and Immunotherapy for Improving Survival Rates in Extensive-Stage Small Cell Lung Cancer

    Lung cancer

    Led by National Cancer Center / Cancer Hospital, CAMS. . Start date 2027-01. NCT07928882

    Phase
    Not stated
    Ages
    18 and over
    Where
    Beijing
    Not stated
    18 and over
    Beijing1 listed hospital
  20. Not yet recruiting

    A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer

    Pancreatic cancer

    Led by Ruijin Hospital; 4 listed hospitals as study sites. . Start date 2026-10. NCT07928362

    Phase
    Not stated
    Ages
    18–75
    Where
    Chengdu, Qingdao +2
    Not stated
    18–75
    Chengdu, Qingdao +25 listed hospitals
  21. Recruiting

    Artificial Intelligence-Assisted 4D Dynamic Long-Axial PET Imaging for the Detection of Early Pancreatic Cancer Lesions

    Pancreatic cancer

    Led by Ruijin Hospital. . Start date 2024-11. NCT07925125

    Phase
    Not stated
    Ages
    18–75
    Where
    Shanghai
    Not stated
    18–75
    Shanghai1 listed hospital
  22. Recruiting

    A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors

    Stomach cancerBreast cancer

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sites. . Start date 2024-07. NCT07923214

    Phase
    Phase 1
    Ages
    18 and over
    Where
    Chengdu, Fuzhou +1
    1
    18 and over
    Chengdu, Fuzhou +13 listed hospitals
  23. Not yet recruiting

    GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis

    Stomach cancer

    Led by Ruijin Hospital. . Start date 2026-11. NCT07923396

    Phase
    Phase 1
    Ages
    18 and over
    Where
    Shanghai
    1
    18 and over
    Shanghai1 listed hospital
  24. Enrolling by invitation

    Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors

    Lung cancer

    Lead sponsor is not a listed hospital; 1 listed hospital as study site. . Start date 2026-01. NCT07920822

    Phase
    Phase 1
    Ages
    18–75
    Where
    Wuhan
    1
    18–75
    Wuhan1 listed hospital
  25. Recruiting

    Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

    Stomach cancer

    Led by Union Hospital. . Start date 2025-07. NCT07920224

    Phase
    Phase 2
    Ages
    18–75
    Where
    Wuhan
    2
    18–75
    Wuhan1 listed hospital
  26. Recruiting

    Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery

    Breast cancer

    Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sites. . Start date 2023-07. NCT07920094

    Phase
    Not stated
    Ages
    18–70, women only
    Where
    Hangzhou, Jinhua +3
    Not stated
    18–70Women only
    Hangzhou, Jinhua +311 listed hospitals
  27. Not yet recruiting

    A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis

    Myasthenia gravis

    Led by Tongji Hospital. . Start date 2026-12. NCT07917923

    Phase
    Early phase 1
    Ages
    18–65
    Where
    Wuhan
    Early phase 1
    18–65
    Wuhan1 listed hospital
  28. Not yet recruiting

    Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features

    Nasopharyngeal carcinoma

    Led by Zhongshan City People's Hospital; 1 listed hospital as study site. . Start date 2026-11. NCT07918755

    Phase
    Not stated
    Ages
    18 and over
    Where
    Nanning, Zhongshan
    Not stated
    18 and over
    Nanning, Zhongshan2 listed hospitals
  29. Not yet recruiting

    Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG

    Coronary heart disease

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sites. . Start date 2026-12. NCT07918781

    Phase
    Not stated
    Ages
    18 and over
    Where
    Beijing, Changsha +2
    Not stated
    18 and over
    Beijing, Changsha +24 listed hospitals
  30. Not yet recruiting

    Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT

    B-cell acute lymphoblastic leukaemia

    Led by Peking University People's Hospital; 1 listed hospital as study site. . Start date 2026-11. NCT07919470

    Phase
    Not stated
    Ages
    14–65
    Where
    Beijing, Langfang
    Not stated
    14–65
    Beijing, Langfang2 listed hospitals

“Posted” is when the study first appeared on ClinicalTrials.gov; “updated” is its latest change there. Ages and sex are the registered criteria, not a check of who can join. The order is not a ranking.